Intracoronary administration of metabolic agents in the treatment of acute coronary syndrome
The article presents the new possibilities of preventing the onset of irreversible myocardial damage during ischemia and effective approaches undertaken in the early reperfusion period (per - and postconditioning of the myocardium) through coronary the introduction of cardioprotective drugs. Practit...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Izdatelstvo OKI
2018-05-01
|
| Series: | Качественная клиническая практика |
| Subjects: | |
| Online Access: | https://www.clinvest.ru/jour/article/view/92 |
| _version_ | 1797262129585192960 |
|---|---|
| author | A. A. Spasski A. A. Mikhaylov A. Yu. Kharitonov |
| author_facet | A. A. Spasski A. A. Mikhaylov A. Yu. Kharitonov |
| author_sort | A. A. Spasski |
| collection | DOAJ |
| description | The article presents the new possibilities of preventing the onset of irreversible myocardial damage during ischemia and effective approaches undertaken in the early reperfusion period (per - and postconditioning of the myocardium) through coronary the introduction of cardioprotective drugs. Practitioners need medicines, which have fewer complications and are universal this is by far the metabolic drugs. The author surveyed 300 patients (three groups) with acute coronary syndrome (ACS) hospitalized no later than 4 hours from the beginning of anginal attack. Patients in group I (n=109) in the prehospital phase was carried out by the system tromboliticescoy therapy (TLT) in combination with intravenous etilmetilgidroksipiridina succinate (200 mg), which the hospital performed mechanical recanalization and angioplasty of the infarct-related coronary artery (IRA) with intracoronary introduction of etilmetilgidroksipiridina succinate (200 mg). Patients in group II (n=101) etilmetilgidroksipiridina succinate (200 mg) primary intracoronary injected during the endovascular procedure. Patients III (control) group (n=90) was carried out only angioplasty of the IRA. Conclusions: the effect of restoration of coronary circulation set after conducted thrombolytic therapy with intracoronary administration of etilmetilgidroksipiridina succinate immediately after successful angioplasty of the IRA, which helped to restore adequate blood flow to prevent relapses and extension of the necrosis zone, transition to a higher angina functional classes. |
| first_indexed | 2024-04-24T23:52:12Z |
| format | Article |
| id | doaj.art-a606291c7aab415892d58bf1f72c98ae |
| institution | Directory Open Access Journal |
| issn | 2588-0519 2618-8473 |
| language | Russian |
| last_indexed | 2024-04-24T23:52:12Z |
| publishDate | 2018-05-01 |
| publisher | Izdatelstvo OKI |
| record_format | Article |
| series | Качественная клиническая практика |
| spelling | doaj.art-a606291c7aab415892d58bf1f72c98ae2024-03-14T18:09:04ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732018-05-0103353792Intracoronary administration of metabolic agents in the treatment of acute coronary syndromeA. A. Spasski0A. A. Mikhaylov1A. Yu. Kharitonov2Общероссийская общественная организация «Российское научное медицинское общество терапевтов»Общероссийская общественная организация «Российское научное медицинское общество терапевтов»Общероссийская общественная организация «Российское научное медицинское общество терапевтов»The article presents the new possibilities of preventing the onset of irreversible myocardial damage during ischemia and effective approaches undertaken in the early reperfusion period (per - and postconditioning of the myocardium) through coronary the introduction of cardioprotective drugs. Practitioners need medicines, which have fewer complications and are universal this is by far the metabolic drugs. The author surveyed 300 patients (three groups) with acute coronary syndrome (ACS) hospitalized no later than 4 hours from the beginning of anginal attack. Patients in group I (n=109) in the prehospital phase was carried out by the system tromboliticescoy therapy (TLT) in combination with intravenous etilmetilgidroksipiridina succinate (200 mg), which the hospital performed mechanical recanalization and angioplasty of the infarct-related coronary artery (IRA) with intracoronary introduction of etilmetilgidroksipiridina succinate (200 mg). Patients in group II (n=101) etilmetilgidroksipiridina succinate (200 mg) primary intracoronary injected during the endovascular procedure. Patients III (control) group (n=90) was carried out only angioplasty of the IRA. Conclusions: the effect of restoration of coronary circulation set after conducted thrombolytic therapy with intracoronary administration of etilmetilgidroksipiridina succinate immediately after successful angioplasty of the IRA, which helped to restore adequate blood flow to prevent relapses and extension of the necrosis zone, transition to a higher angina functional classes.https://www.clinvest.ru/jour/article/view/92кардиопротекцияметаболические препаратывнутрикоронарное введениеэтилметилгидроксипиридина сукцинатcardioprotectionmetabolic drugsintracoronary administrationetilmetilgidroksipiridina succinate |
| spellingShingle | A. A. Spasski A. A. Mikhaylov A. Yu. Kharitonov Intracoronary administration of metabolic agents in the treatment of acute coronary syndrome Качественная клиническая практика кардиопротекция метаболические препараты внутрикоронарное введение этилметилгидроксипиридина сукцинат cardioprotection metabolic drugs intracoronary administration etilmetilgidroksipiridina succinate |
| title | Intracoronary administration of metabolic agents in the treatment of acute coronary syndrome |
| title_full | Intracoronary administration of metabolic agents in the treatment of acute coronary syndrome |
| title_fullStr | Intracoronary administration of metabolic agents in the treatment of acute coronary syndrome |
| title_full_unstemmed | Intracoronary administration of metabolic agents in the treatment of acute coronary syndrome |
| title_short | Intracoronary administration of metabolic agents in the treatment of acute coronary syndrome |
| title_sort | intracoronary administration of metabolic agents in the treatment of acute coronary syndrome |
| topic | кардиопротекция метаболические препараты внутрикоронарное введение этилметилгидроксипиридина сукцинат cardioprotection metabolic drugs intracoronary administration etilmetilgidroksipiridina succinate |
| url | https://www.clinvest.ru/jour/article/view/92 |
| work_keys_str_mv | AT aaspasski intracoronaryadministrationofmetabolicagentsinthetreatmentofacutecoronarysyndrome AT aamikhaylov intracoronaryadministrationofmetabolicagentsinthetreatmentofacutecoronarysyndrome AT ayukharitonov intracoronaryadministrationofmetabolicagentsinthetreatmentofacutecoronarysyndrome |